Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers C > Headlines for Covance Inc. > News item |
Covance at buy by Jefferies
Covance was rated at buy with a $64 price target by Jefferies & Co., Inc. analyst David Windley after touring the company's Madison, Wis., facility where toxicology and preclinical work are conducted. Jefferies believes the company's valuation is in line with its consistently outstanding results over the long term. Shares of the Princeton, N.J., drug development services company were up $0.36, or 0.62%, at $58.02 on volume of 426,400 shares versus the three-month running average of 437,947 shares. (NYSE: CVD)
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.